HRP20020332B1 - Oral solution containing galanthamine and a sweetening agent - Google Patents
Oral solution containing galanthamine and a sweetening agentInfo
- Publication number
- HRP20020332B1 HRP20020332B1 HR20020332A HRP20020332A HRP20020332B1 HR P20020332 B1 HRP20020332 B1 HR P20020332B1 HR 20020332 A HR20020332 A HR 20020332A HR P20020332 A HRP20020332 A HR P20020332A HR P20020332 B1 HRP20020332 B1 HR P20020332B1
- Authority
- HR
- Croatia
- Prior art keywords
- solution containing
- oral solution
- sweetening agent
- containing galanthamine
- galanthamine
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 4
- 235000003599 food sweetener Nutrition 0.000 title abstract 2
- 229960003980 galantamine Drugs 0.000 title abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 2
- 229940100688 oral solution Drugs 0.000 title abstract 2
- 239000003765 sweetening agent Substances 0.000 title abstract 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title 1
- 239000007788 liquid Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203512 | 1999-10-26 | ||
| PCT/EP2000/010203 WO2001030318A1 (en) | 1999-10-26 | 2000-10-16 | Oral solution containing galanthamine and a sweetening agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20020332A2 HRP20020332A2 (en) | 2004-02-29 |
| HRP20020332B1 true HRP20020332B1 (en) | 2011-02-28 |
Family
ID=8240778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020332A HRP20020332B1 (en) | 1999-10-26 | 2002-04-15 | Oral solution containing galanthamine and a sweetening agent |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1237539B1 (is) |
| JP (1) | JP2003512415A (is) |
| KR (1) | KR100502391B1 (is) |
| CN (1) | CN1200691C (is) |
| AR (1) | AR026243A1 (is) |
| AT (1) | ATE306904T1 (is) |
| AU (1) | AU780826C (is) |
| BG (1) | BG65792B1 (is) |
| BR (1) | BR0015025A (is) |
| CA (1) | CA2388830C (is) |
| CZ (1) | CZ301996B6 (is) |
| DE (1) | DE60023341T2 (is) |
| DK (1) | DK1237539T3 (is) |
| EA (1) | EA005683B1 (is) |
| EE (1) | EE05230B1 (is) |
| ES (1) | ES2250211T3 (is) |
| HK (1) | HK1049619A1 (is) |
| HR (1) | HRP20020332B1 (is) |
| HU (1) | HUP0203484A3 (is) |
| IL (2) | IL149310A0 (is) |
| IS (1) | IS2628B (is) |
| MX (1) | MXPA02004149A (is) |
| NO (1) | NO332096B1 (is) |
| PL (1) | PL201694B1 (is) |
| SI (1) | SI1237539T1 (is) |
| SK (1) | SK285643B6 (is) |
| TW (1) | TW592725B (is) |
| UA (1) | UA76095C2 (is) |
| WO (1) | WO2001030318A1 (is) |
| ZA (1) | ZA200203313B (is) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| CA2535613A1 (en) * | 2003-08-13 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Treatment of sleep disorders with cholinesterase inhibitors |
| EP1763337A2 (en) * | 2003-12-31 | 2007-03-21 | Actavis Group HF | Immediate, controlled and sustained release formulations of galanthamine |
| US8709521B2 (en) * | 2007-05-22 | 2014-04-29 | The Coca-Cola Company | Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles |
| SI2667715T1 (sl) * | 2011-01-27 | 2017-11-30 | Neuren Pharmaceuticals Limited | Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline |
| US20140107130A1 (en) * | 2012-10-11 | 2014-04-17 | Antrim Pharmaceuticals, LLC | Oral Solution Formulations of Aripiprazole |
| JP6457582B2 (ja) * | 2017-04-14 | 2019-01-23 | エルメッド エーザイ株式会社 | ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449247A2 (de) * | 1990-03-29 | 1991-10-02 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus |
| EP0556057A1 (en) * | 1992-02-14 | 1993-08-18 | McNEIL-PPC, INC. | Aqueous pharmaceutical suspension for pharmaceutical actives |
| EP0653427A1 (en) * | 1993-10-15 | 1995-05-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Galanthamine derivatives, a process for their preparation and their use as medicaments |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10273435A (ja) * | 1997-01-29 | 1998-10-13 | Fujisawa Pharmaceut Co Ltd | 内服用液剤 |
-
2000
- 2000-10-16 DK DK00975872T patent/DK1237539T3/da active
- 2000-10-16 MX MXPA02004149A patent/MXPA02004149A/es active IP Right Grant
- 2000-10-16 DE DE60023341T patent/DE60023341T2/de not_active Expired - Lifetime
- 2000-10-16 TW TW089121526A patent/TW592725B/zh not_active IP Right Cessation
- 2000-10-16 ES ES00975872T patent/ES2250211T3/es not_active Expired - Lifetime
- 2000-10-16 CZ CZ20021329A patent/CZ301996B6/cs not_active IP Right Cessation
- 2000-10-16 SI SI200030782T patent/SI1237539T1/sl unknown
- 2000-10-16 EE EEP200200213A patent/EE05230B1/xx unknown
- 2000-10-16 JP JP2001532738A patent/JP2003512415A/ja active Pending
- 2000-10-16 HU HU0203484A patent/HUP0203484A3/hu unknown
- 2000-10-16 PL PL362849A patent/PL201694B1/pl unknown
- 2000-10-16 KR KR10-2002-7003258A patent/KR100502391B1/ko active IP Right Grant
- 2000-10-16 EP EP00975872A patent/EP1237539B1/en not_active Expired - Lifetime
- 2000-10-16 UA UA2002054064A patent/UA76095C2/uk unknown
- 2000-10-16 EA EA200200486A patent/EA005683B1/ru not_active IP Right Cessation
- 2000-10-16 CN CNB008147388A patent/CN1200691C/zh not_active Expired - Lifetime
- 2000-10-16 SK SK530-2002A patent/SK285643B6/sk not_active IP Right Cessation
- 2000-10-16 BR BR0015025-8A patent/BR0015025A/pt not_active Application Discontinuation
- 2000-10-16 CA CA002388830A patent/CA2388830C/en not_active Expired - Lifetime
- 2000-10-16 WO PCT/EP2000/010203 patent/WO2001030318A1/en active IP Right Grant
- 2000-10-16 AU AU13849/01A patent/AU780826C/en not_active Expired
- 2000-10-16 IL IL14931000A patent/IL149310A0/xx active IP Right Grant
- 2000-10-16 AT AT00975872T patent/ATE306904T1/de active
- 2000-10-25 AR ARP000105621A patent/AR026243A1/es not_active Application Discontinuation
-
2002
- 2002-02-28 IS IS6291A patent/IS2628B/is unknown
- 2002-03-20 BG BG106534A patent/BG65792B1/bg unknown
- 2002-04-15 HR HR20020332A patent/HRP20020332B1/xx not_active IP Right Cessation
- 2002-04-24 IL IL149310A patent/IL149310A/en unknown
- 2002-04-25 ZA ZA200203313A patent/ZA200203313B/xx unknown
- 2002-04-26 NO NO20022003A patent/NO332096B1/no not_active IP Right Cessation
-
2003
- 2003-03-10 HK HK03101718A patent/HK1049619A1/xx not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449247A2 (de) * | 1990-03-29 | 1991-10-02 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus |
| EP0556057A1 (en) * | 1992-02-14 | 1993-08-18 | McNEIL-PPC, INC. | Aqueous pharmaceutical suspension for pharmaceutical actives |
| EP0653427A1 (en) * | 1993-10-15 | 1995-05-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Galanthamine derivatives, a process for their preparation and their use as medicaments |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020198B1 (en) | Moxifloxacin formulation containing common salt | |
| EP1135173A4 (en) | MEDICINAL AEROSOL FORMULATION | |
| MY135119A (en) | Stabilized oral suspension formulation | |
| AP9801169A0 (en) | N-hydroxy-B-sulfonyl propionamide derivatives. | |
| WO2001041737A3 (en) | Solid oral dosage form | |
| DZ2509A1 (fr) | Analogues peptidiques de la lh-rh leur utilisationet les compositions pharmaceutiques les contenant. | |
| PL337794A1 (en) | Pharmaceutic agent for oral administration containing an active substance and cyclodextrin | |
| HK1074163A1 (en) | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | |
| HRP20010878B1 (en) | Ziprasidone suspension | |
| PL346764A1 (en) | New oral formulation for 5-ht4 | |
| HUP9700005A3 (en) | 2-ureido-benzamide derivatives and pharmaceutical compositions containing them as active agent | |
| HRP20020332B1 (en) | Oral solution containing galanthamine and a sweetening agent | |
| HRP20040171A2 (en) | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof | |
| MXPA03005405A (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina. | |
| HRP20010764B1 (en) | Prucalopride oral solution | |
| HUP0200729A3 (en) | Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them | |
| MA26447A1 (fr) | Analogues peptidiques de la lh-rh, leurs utilisations et compositions pharmaceutiques en contenant | |
| HUP0004362A2 (hu) | Karbamazepint vagy származékait tartalmazó parenterális készítmények | |
| MXPA03005441A (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina (2). | |
| WO2001039741A3 (de) | Mitomycin c-lösung | |
| HUP9902633A3 (en) | Phenylethanolaminotetralincarboxamide derivatives and pharmaceutical compositions containing them | |
| MY152490A (en) | New oral formulation | |
| FR2800736B1 (fr) | Derives d'oligobenzimidazoles, les compositions les contenant et leurs utilisations | |
| HUP0001536A3 (en) | Sulfonamide and carboxamide derivatives and pharmaceutical compositions containing the same as the active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20180928 Year of fee payment: 19 |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20191030 Year of fee payment: 20 |
|
| PB20 | Patent expired after termination of 20 years |
Effective date: 20201016 |